Januvia
E468957
Januvia is a prescription medication (sitagliptin) used to help control blood sugar levels in adults with type 2 diabetes.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Januvia canonical | 2 |
| sitagliptin | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4784889 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Januvia Context triple: [Merck & Co., notableDrug, Januvia]
-
A.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
B.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
C.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Januvia Target entity description: Januvia is a prescription medication (sitagliptin) used to help control blood sugar levels in adults with type 2 diabetes.
-
A.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
B.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
C.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
DPP-4 inhibitor
ⓘ
antihyperglycemic agent ⓘ brand name drug ⓘ prescription medication ⓘ |
| affects | DPP-4 enzyme ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| canBeUsedAs | monotherapy for type 2 diabetes ⓘ |
| canBeUsedInCombinationWith |
insulin
ⓘ
metformin ⓘ sulfonylureas ⓘ thiazolidinediones ⓘ |
| canCause | hypoglycemia when used with insulin or sulfonylureas ⓘ |
| commonAdverseEffect |
gastrointestinal discomfort
ⓘ
headache ⓘ nasopharyngitis ⓘ upper respiratory tract infection ⓘ |
| contraindication | known hypersensitivity to sitagliptin ⓘ |
| developedBy | Merck & Co. ⓘ |
| dosageForm | tablet ⓘ |
| doseAdjustmentRequiredIn | renal impairment ⓘ |
| FDAApprovalYear | 2006 ⓘ |
| hasActiveIngredient | sitagliptin phosphate ⓘ |
| hasATCCode | A10BH01 ⓘ |
| hasGenericName |
sitagliptin
ⓘ
linked to:
Januvia
|
| indicatedFor | type 2 diabetes mellitus ⓘ |
| marketedBy | Merck & Co. ⓘ |
| mechanismOfAction |
decreases hepatic glucose production
ⓘ
increases incretin hormone levels ⓘ increases insulin release in a glucose-dependent manner ⓘ inhibits dipeptidyl peptidase-4 (DPP-4) ⓘ |
| notIndicatedFor |
diabetic ketoacidosis
ⓘ
type 1 diabetes mellitus ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| requires | prescription ⓘ |
| requiresMonitoringOf | renal function ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousAdverseEffect |
acute pancreatitis
ⓘ
hypersensitivity reactions ⓘ severe joint pain ⓘ |
| takenOnceDaily | true ⓘ |
| takenWith | or without food ⓘ |
| targetPopulation | adults with type 2 diabetes ⓘ |
| therapeuticClass | oral antidiabetic drug ⓘ |
| typicalDose | 100 mg once daily in adults with normal renal function ⓘ |
| usedFor |
glycemic control in adults with type 2 diabetes
ⓘ
lowering blood glucose levels ⓘ |
| warning |
risk of hypersensitivity reactions including anaphylaxis
ⓘ
risk of pancreatitis ⓘ risk of severe arthralgia ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Januvia Description of subject: Januvia is a prescription medication (sitagliptin) used to help control blood sugar levels in adults with type 2 diabetes.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Januvia